JAKAFI XR 44 mg/1
ruxolitinib · TABLET, EXTENDED RELEASE · Incyte Corporation
No Recall History
Plain English
JAKAFI XR is a tablet, extended release containing ruxolitinib at 44 mg/1, taken oral. Manufactured by Incyte Corporation.
Key Facts
- Brand Name
- JAKAFI XR
- Generic Name
- ruxolitinib
- NDC Code (Product)
50881-044- Manufacturer
- Incyte Corporation
- Strength
- 44 mg/1
- Dosage Form
- TABLET, EXTENDED RELEASE
- Route
- ORAL
- Marketing Status
- Application #
- NDA217180
- Drug Class
- Kinase Inhibitor [EPC]; Janus Kinase Inhibitor [EPC]
- Marketing Start
- 05/01/2026
Recall History
No Recall HistoryFrequently Asked Questions
What is JAKAFI XR used for?
JAKAFI XR contains ruxolitinib. It is a tablet, extended release taken oral. Consult your doctor for specific uses.
Is JAKAFI XR a controlled substance?
JAKAFI XR is not classified as a controlled substance by the DEA.
What is the generic name for JAKAFI XR?
The generic name for JAKAFI XR is ruxolitinib. There are 6 other brand versions of ruxolitinib.
What is the NDC code for JAKAFI XR 44 mg/1?
The NDC (National Drug Code) for JAKAFI XR 44 mg/1 is 50881-044, listed by Incyte Corporation.